宇高　恵子

Original Articles

○Lipid-mediated presentation of MHC class II molecules guides thymocytes to the CD4 lineage.　Komaniwa S., Hayashi H., Kawamoto H., Sato S.B., Ikawa T., Katsura Y. and Udaka K.　Eur J Immunol 39,1−7, 2009.

○Biochemical visualization of cell surface molecular clustering in living cells.　Kotani N., Gu J., Isaji T., Udaka K., Taniguchi N. and Honke K.　Proc Natl Acad Sci USA 105(21), 7405-7409, 2008.

○　Human leukocyte antigen-G, a ligand for the natural killer receptor KIR2DL4, is expressed by eutopic endometrium only in the menstrual phase.　Kawashima M., Maeda N., Adachi Y., Takeuchi T., Yamamoto Y., Izumiya C., Hayashi K., Furihata M., Udaka K. and Fukaya T.　Fertil Steril, 2008 [Epub ahead of print]

○Wilms’ tumor 1 gene expression is increased in hepatocellular carcinoma and associated with poor prognosis.　Sera T., Hiasa Y., Mashiba T., Tokumoto Y., Hirooka M., Konishi I., Matsuura B., Michitaka K., Udaka K. and Onji M.　Eur J Cancer, 44(4),600-608, 2008.

○ Wilms’ tumor gene WT1 peptide-based immunotherapy induced a minimal response in a  patient with advanced therapy-resistant multiple myeloma.　Tsuboi A., Oka Y., Nakajima H., ukuda Y., Elisseeva O.A., Yoshihara S., Hosen N., Ogata A., Kito K., Fujiki F., Nishida S., Shirakata T., Ohno S., Yasukawa M., Oji Y., Kawakami M., Morita S., Sakamoto J., Udaka K., Kawase I. and Sugiyama H.　Int J Hematol 86(5), 414-417, 2007.

○ Potent CTL induction by a whole cell pertussis vaccine in anti-tumor peptide immunotherapy. Yano A., Komatsu T. Ishibashi M. and Udaka K. Microbiology and Immunology 51(7) , 685-699, 2007.

○ WT1 (Wilms' Tumor 1) peputide immunotherapy for renal cell carcinoma. Iiyama T., Takeda S., Udaka K., Takeuchi T., Adachi Y.C., Shuin T., Ohtsuki Y., Oka Y., Tsuboi A., Nakatsuka S., Elisseeva O.A., Oji Y., Nakajima H., Kawakami M., Nishida S., Shirakata T., and Sugiyama H. Microbiology and Immunology 51(5), 59-530, 2007.

○ Identification and characterization of a WT1(Wilms' tumor gene) protein-derived HLA-DR1 *0405-restricted 16-mer helper peptide that prmotes the induction and activation of WT1-Specific cytoxic T lymphocytes. Fujiki F., Oka Y., Tsuboi A., Kawakami M.., Kawakatsu M., Nakajima H., Elisseeva O.A., Harada Y., Ito K., Li Z., Tatsumi N., Sakaguchi N., Fujioka T., Masuda T., Yasukawa M., Udaka K., Kawase I., Oji Y. and Sugiyama H. Journal of Immunotherapy 30(3), 282-293, 2007.

○ Identification of CTL epitopes in hepatitis C virus by a genome-wide computational acanning and a rational design of peptide vaccine. Mashiba T., Udaka K., Hirachi Y., Miyakawa T., Satta Y., Osada T., Kataoka S., Kohara M. and Onji M. Immunogenetics 59, 197-209, 2007.

○ Structure of the cadherin-rerated neuronal receptor/protocadherin-α first cadherin domain reveals diversity across cadherin families. Morishita H., Umitsu M., Murata Y., Shibata N., Udaka K., Higuchi Y., Akutsu H., Yamaguchi T. and Ikegami T. J. Biol. Chem 281(44), 33650-33663, 2006.

○　A phase I/II trial of a WT1(Wilms' Tumor Gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data. Morita S., Oka Y., Tsuboi A., Kawakami M., Maruno M., Izumoto S., Osaki T., Taguchi T., Ueda T., Myoui A., Nishida S., Shirakawa T., Ohno S., Oji Y., Aozasa K., Hatazawa J., Udaka K., Yoshikawa H., Yoshimine T., Noguchi S., Kawase I., Nakatsuka S., Sugiyama H. and Sakamoto J. Jpn. J. Clin. Oncol. 36(4), 231-236, 2006.

○ Improving MHC binding peptide prediction by incorporating binding data of auxiliary MHC molecules. Zhu S., Udaka K., Sidney J., Sette A., Aoki-Kinoshita K.F. and Mamitsuka H. Bioinfomatics 22(13), 1648-1655, 2006.

○WT235 , a ninemer peptide derived from Wilms' tumor gene product, is a candidate peptide for the vaccination of HLA-A*0201-positive patients with hematopoietic malignancies. Li Z., Oka Y., Tsuboi A., Masuda T., Tatsumi N., Kawakami M., Fujioka T., Sakaguchi N., Nakajima H., Fujiki F., Udaka K., Oji Y., Kawase I. and Sugiyama H. Int. J. Hematol. 82, 458-459, 2005.

○Fyn regulated eosinophil infiltration into the conjunctiva by downregulating the Th2 response.  A. Fukushima, T. Yamaguchi, A. Ozaki, T. Taniguchi, K. Udaka and H. Ueno   Grafes Arch. Clin. Exp. Ophthalmol. 243, 1043-1049, 2005.

○ Mice lacking the IFN-gamma receptor or fyn develop severe experimental autoimmune uveoretinitis characterized by different immune responses. A. Fukushima, T. Yamaguchi, W. Ishida, K. Fukata, K. Udaka and H. Ueno  Immunogenetics  57(5),337-343, 2005.

○ 1H, 13C and 15N resonance assignments of the first cadherin domain of Cadherin-related neuronal receptor CNR)/ protocadherin alpha. M. Umitsu, H. Morishita, Y. Murata, K. Udaka, H. Akutsu, T. Yagi and T. Ikegami  J. Biomol. NMR. 31(4),365-366,2005.

○ Induction of WT1(Wilms’ tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Y. Oka, A. Tsuboi, T. Taguchi, T. Osaki, T. kyo, H. Nakajima, O.A.Elisseeva, Y. Oji, M. Kawakami, K. Ikegami, N. Hosen,  S. Yoshihara, F. Wu, F. Fujiki, M. Murakami, T. Masuda, S. Nishida, T. Shirakawa, S. Nakatsuka, A. Sasaki, K. Udaka, H. Dohy, K. Aozasa, S. Noguchi, I. Kawase and H. Sugiyama  Proc. Natl. Acad. Sci USA, 21, 13885-13890, 2004.

○ WT1 peptide-based immunotherapy for patients with lung cancer: Report of two case. A. Tsuboi, Y. Oka, T. Osaki, T. Kumagai, I. Tachibana, S. Hayashi, M. Murakami, H. Nakajima, O.A. Elisseeva, W. Fei, T. Masuda, M. Yasukawa, Y. Oji, M. Kawakami, N. Hosen, K. Ikegame, S. Yoshihara, K. Udaka, S.-I. Nakatsuka, K. Aozasa, I. Kawase and H. Sugiyama. Microbiol. Immunol.  48, 175-184, 2004.

○ Wilms Tumor Gene Peptide-Based Immunotherapy for Patients with Overt Leukemia from Myelodysplastic Syndrome (MDS) or MDA with Myelofibrosis.  Y. Oka, A. Tsuboi, M. Murakami, M. Hirai, N. Tominaga, H. Nakajima, O.A. Elisseeva, T. Yasukawa, H. Ogawa, I. Kawase and H. Sugiyama.     Int. J. Hematology  78,56-61, 2003.

○ Actin-rich spherical extrusion induced in Okadaic acid-treated K562 cells by crosslinking of membrane microdomains. T. Baba, K. Udaka, N. Terada,  H. Ueda, Y. Fujii, S. Ohno and S.B. Sato  J. Histochem. Cytochem. 51, 1-8, 2003.

○ Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues. A. Tsuboi, Y. Oka, K. Udaka, M. Murakami, T. Masuda, A. Nakano, H. Nakajima, M. Yasukawa, A. Hiraki, Y. Oji, M. Kawakami, N. Hosen, T. Fujioka, F. Wu, Y. Taguchi, S. Nishida, M. Asada, H. Ogawa, I. Kawase and H. Sugiyama  Cancer Immunol. Immunother.51(11-12), 614-620, 2002.

○ Empirical evaluation of a dynamic experiment design method for prediction of MHC class I-binding peptides.Keiko Udaka, Hiroshi Mamitsuka, Yukinobu Nakaseko and Naoki Abe. J Immunol, 169, 5744-5753, 2002.

○ Humoral immune responses against Wilms’ tumor gene WT1 product in patients with hematopoietic malignancies. O. A Elisseeva, Y. Oka, A. Tsuboi K. Ogata, F. Wu, E.H. Kim, T. Soma H. Tamaki, M. Kawakami, Y. Oji, N. Hosen, T. Kubota M. Nakagawa, T. Yamagami, A. Hiraoka, M. Tsukaguchi, K. Udaka, H. Ogawa, T. Kishimoto, T. Nomura and H. Sugiyama  Blood 99, 3272-3279, 2002.

○ NMR study on the interaction between MHC class I protein and its antigen peptide. Masatoshi Nakagawa, Kaori Chiba-Kamoshida, Keiko Udaka and Hiroshi Nakanishi. Biochem Biophys Res Commun 278, 609-613, 2000.

○ An automated prediction of MHC class I-binding peptides based on positional scanning with peptide libraries. K. Udaka, K.-H. Wiesmuller, S. Kienle, G. Jung, H. Tamamura, H. Yamagishi, K. Okumura, P. Walden, T. Suto and T. Kawasaki. Immunogenetics, 51(10), 816-828, 2000.

○ Cytotoxic T-lymphocyte responses elicited to Wilms’ tumor gene WT1 product by DNA vaccination. A. Tsuboi, Y. Oka, H. Ogawa, O.A. Elisseeva, H. Li, K. Kawasaki, K. Aozasa, T. Kishimoto, K. Udaka, and H. Sugiyama  J. Clin. Immunol. 20(3), 195-202, 2000.

○ Efficient induction of peptide specific cytotoxic T lymphocytes by LPS activated spleen cells. Kiyokazu Kakugawa, Keiko Udaka, Kosuke Nakashima, Kayo Inaba, Yoshihiro Oka, Haruo Sugiyama, Hirokazu Tamamura, Hideo Yamagishi. Microbiol. Immunol. 44, 123-133, 2000.

○ Cancer immunotherapy targeting Wilms' tumor gene WT1 product. Keiko Udaka, Yoshihiro Oka, Akihiro Tsuboi, Olga Elisseeva, Hiroyasu Ogawa, Katsuyuki Aozasa, Tadamitsu Kishimoto and Haruo Sugiyama. J. Immunol. 164, 1873-1880, 2000.

○ Human cytotoxic T cell response specific for peptides of wild-type Wilms’ tumor gene (WT1) product. Y. Oka, O.A. Elisseeva, A. Tsuboi, H. Ogawa, H. Tamaki, H. Li, Y. Oji, E.H. Kim, T. Soma, M. Asada, K. Ueda, E. Maruya, H. Saji, T. Kishimoto, K. Udaka and H. Sugiyama Immunogenetics, 51, 99-107, 2000.

○ Dystrophin acts as a transplantation rejection antigen in dystrophin-deficient mice : Implication for gene therapy. Y. Ohtsuka, K. Udaka, Y. Yamashiro, H. Yagita and K. Okumura. J. Immunol. 160, 4635-4640, 1998.

○ Impaired induction of cytotoxic T lymphocytes by antagonism of a weak agonist borne by a variant hepatitis C virus epitope. Takashi Kaneko, Takashi Moriyama, Keiko Udaka, KazumasaHiroishi, Hiroto Kita, Hiroaki Okamoto, Hideo Yagita, Ko Okumura and MichioImawari.Eur. J. Immunol.　27, 1782-1787, 1997.

○ Self MHC-restricted peptides recognized by an alloreactive T lymphocyte clone.KeikoUdaka, Karl-Heinz Wiesmuller, Stefan Kienle, Gunther Jung and Peter Walden. J. Immunol. 157, 670-678, 1996

○ Tolerance to amino acid variations in peptides binding to the MHC class I proetin H-2Kb.Keiko Udaka, Karl-Heinz Wiesmuller, Stefan Kienle, Gunther Jung and Peter Walden.J. Biol. Chem. 270, 24130-24134, 1995

○ Decrypting the structure of MHC-I restricted CTL epitopes with complex peptide libraries. Keiko Udaka, Karl-Heinz Wiesmuller, Stefan Kienle, Gunther Jung and Peter Walden. J. Exp. Med. 181, 2097-2108. 1995.

○ CD4, CD8 T cells and T cells are responsible for cytotoxicity raised in 2-microglobulin deficient mice against cells having normal MHC class I expression.KeikoUdaka, SuzanaMarusic-Galesic, Peter Walden.J. Immunol. 153 : 2843 - 2850, 1994.

○ A ubiquitous protein is the source of naturally occurring peptides that are recognized by a CD8+ T cell clone.KeikoUdaka, Theodore J. Tsomides, Peter Walden, Naomi Fukusen and Herman. N. Eisen. Proc. Natl. Acad. Sci. USA 90, 11272-11276, 1993.

○ A naturally occurring peptide recognized by alloreactive CD8+ cytotoxic T lymphocytes in association with a class I MHC protein. Keiko Udaka, Theodore J. Tsomides, Herman N. Eisen.Cell. 69, 989-998, 1992.




Review Articles

○ Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancers. Oka Y., Tsuboi A., Kawakami M., Ellisseeva O.A., Nakajima H., Udaka K., Kawase I., Oji Y. and Sugiyama H. Current medicinal Chemistry 3, 2345-2352, 2006.

○ Cellular and humoral immune responses against Wilms' tumor gene WT1 product (WT1) which overexpresses in various kinds of malignant neoplasms --- Toward the development of cancer vaccine targeting WT1 ---. Oka Y. Tsuboi A., Elisseeva O,A., Oji Y., Udaka K. and Sugiyama H. Recent Res. Devel. Immunology 5, 97-114, 2003.

○ WT1 as a novel target antigen for cancer immunotherapy. Oka Y., Tsuboi A., Elisseeva O.A., Udaka K. and Sugiyama H. Current Cancer Drug Targets 2, 45-54, 2002.

○ Decrypting class I MHC-bound peptides with peptide libraries. K. Udaka.
TiBS (Trends in Biochemical Sciences ) 21, 7-11, 1996.